


PRELIMINARY AMENDMENT

DIVISIONAL APPLN OF APPLN NO. 07/700,895


IN THE CLAIMS:

Please add claims 52-64 as follows.

~~--52.~~ Prostaglandins E represented by a general formula:



B6 in which X represents:



R₁ represents: a hydrogen atom, a physiologically acceptable saturated residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;

R₂ represents: a hydrogen atom or a methyl group;

R₃ represents: a hydroxyl or hydroxymethyl group;

PRELIMINARY AMENDMENT

DIVISIONAL APPLN OF APPLN NO. 07/700,895

R₄ and R₅ each represents: a hydrogen atom, a methyl group or a halogen atom provided that at least one of R₄ and R₅ is a halogen atom; and

R₆ represents: a C₁-C₉ alkyl group which may have a branch or a double bond, or a C₁-C₉ alkyl group having an alkoxy substituent group, the C₂-C₃ bond being a single or double bond.

53. Prostaglandins E as described in claim 1, wherein R₄ and R₅ are halogen atoms.


54. Prostaglandins E as described in claim 1, wherein R₄ and/or R₅ is a fluorine atom.

55. Prostaglandins E as described in claim 1, wherein R₄ or R₅ is a methyl group.

56. Prostaglandins E as described in claim 1, which is 13,14-dihydro-15-keto-PGE having one or more fluorine atom(s) on 16-position or alkyl ester thereof.

57. Prostaglandins E as described in claim 1, being 13,14-dihydro-6,15-diketo-16R,S-fluoro-PGE, or alkyl ester thereof.


58. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E expressed by a general formula:



PRELIMINARY AMENDMENT

DIVISIONAL APPLN OF APPLN NO. 07/700,895

in which X represents:



Ble
R₁ represents: a hydrogen atom, a physiologically acceptable saturated residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;

R₂ represents: a hydrogen atom or a methyl group;

R₃ represents: a hydroxyl or hydroxymethyl group;

R₄ and R₅ each represents: a hydrogen atom, a methyl group or a halogen atom provided that at least one of R₄ and R₅ is a halogen atom; and

R₆ represents: a C₁-C₉ alkyl group which may have a branch or a double bond, or a C₁-C₉ alkyl group having an alkoxy substituent group, the C₂-C₃ bond being a single or double bond.

5/27
59. Prostaglandins E as described in claim 58, wherein R₄ and R₅ are halogen atoms.

60. Prostaglandins E as described in claim 58, wherein R₄ and/or R₅ is a fluorine atom.

61. Prostaglandins E as described in claim 58, wherein R₄ or R₅ is a methyl group.


PRELIMINARY AMENDMENT

DIVISIONAL APPLN OF APPLN NO. 07/700,895


62. Prostaglandins E as described in claim 58, being 13,14-dihydro-15-keto-PGE having one or more fluorine atom(s) on 16-position or alkyl ester thereof.

63. Prostaglandins E as described in claim 58, being 13,14-dihydro-~~6,15-diketo-16R,S-fluoro-PGE, or alkyl ester thereof.~~

¹³
~~64.~~ A treatment of ulcer by administering an anti-ulcer treating effective amount of prostaglandin E to a patient, wherein the prostaglandin E is represented by a formula:



in which X represents:



R₁ represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;